Late Phase Services

Invicro’s clinical capabilities span from early phase, first-in-human through late phase and post-approval studies. We focus on studies containing imaging and pathology-based endpoints requiring robust, independent assessments to ascertain drug efficacy. Our imaging core lab and CAP/CLIA lab-based pathology services solutions support various therapeutic areas including oncology, immuno-oncology, neurology (CNS), cardiovascular, musculoskeletal and gastrointestinal. Our experience comes from years of successful execution of Phase II-IV studies across the development spectrum led by a leadership team with an average of 25 years of industry experience.